Last reviewed · How we verify
lopinavir/ritonavir; nevirapine; Zidovudine; Lamivudine
lopinavir/ritonavir; nevirapine; Zidovudine; Lamivudine is a Antiretroviral combination therapy (protease inhibitor + non-nucleoside reverse transcriptase inhibitor + nucleoside reverse transcriptase inhibitors) Small molecule drug developed by University of British Columbia. It is currently FDA-approved for HIV-1 infection.
This is a combination antiretroviral regimen that inhibits HIV reverse transcriptase and protease to suppress viral replication.
This is a combination antiretroviral regimen that inhibits HIV reverse transcriptase and protease to suppress viral replication. Used for HIV-1 infection.
At a glance
| Generic name | lopinavir/ritonavir; nevirapine; Zidovudine; Lamivudine |
|---|---|
| Sponsor | University of British Columbia |
| Drug class | Antiretroviral combination therapy (protease inhibitor + non-nucleoside reverse transcriptase inhibitor + nucleoside reverse transcriptase inhibitors) |
| Target | HIV protease, HIV reverse transcriptase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | FDA-approved |
Mechanism of action
Lopinavir/ritonavir are protease inhibitors that block HIV protease, preventing viral maturation. Nevirapine and the nucleoside reverse transcriptase inhibitors (zidovudine and lamivudine) inhibit reverse transcriptase, blocking HIV replication at an earlier stage. Together, these agents target multiple steps of the HIV replication cycle to achieve potent viral suppression.
Approved indications
- HIV-1 infection
Common side effects
- Nausea
- Diarrhea
- Rash (nevirapine-related)
- Hepatotoxicity
- Lipid abnormalities
- Anemia (zidovudine-related)
- Peripheral neuropathy
Key clinical trials
- Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2, PHASE3)
- A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments (PHASE4)
- Early Infant HIV Treatment in Botswana (PHASE2, PHASE3)
- Research on the Psychological Status of Patients With HIV-1 Infection
- Antiretroviral Regime for Viral Eradication in Newborns (PHASE4)
- Evaluating Strategies to Reduce Mother-to-Child Transmission of HIV Infection in Resource-Limited Countries (PHASE3)
- Preventing Sexual Transmission of HIV With Anti-HIV Drugs (PHASE3)
- Anti-HIV Drug Regimens and Treatment-Switching Guidelines in HIV Infected Children (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- lopinavir/ritonavir; nevirapine; Zidovudine; Lamivudine CI brief — competitive landscape report
- lopinavir/ritonavir; nevirapine; Zidovudine; Lamivudine updates RSS · CI watch RSS
- University of British Columbia portfolio CI
Frequently asked questions about lopinavir/ritonavir; nevirapine; Zidovudine; Lamivudine
What is lopinavir/ritonavir; nevirapine; Zidovudine; Lamivudine?
How does lopinavir/ritonavir; nevirapine; Zidovudine; Lamivudine work?
What is lopinavir/ritonavir; nevirapine; Zidovudine; Lamivudine used for?
Who makes lopinavir/ritonavir; nevirapine; Zidovudine; Lamivudine?
What drug class is lopinavir/ritonavir; nevirapine; Zidovudine; Lamivudine in?
What development phase is lopinavir/ritonavir; nevirapine; Zidovudine; Lamivudine in?
What are the side effects of lopinavir/ritonavir; nevirapine; Zidovudine; Lamivudine?
What does lopinavir/ritonavir; nevirapine; Zidovudine; Lamivudine target?
Related
- Drug class: All Antiretroviral combination therapy (protease inhibitor + non-nucleoside reverse transcriptase inhibitor + nucleoside reverse transcriptase inhibitors) drugs
- Target: All drugs targeting HIV protease, HIV reverse transcriptase
- Manufacturer: University of British Columbia — full pipeline
- Therapeutic area: All drugs in Infectious Disease / Virology
- Indication: Drugs for HIV-1 infection
- Compare: lopinavir/ritonavir; nevirapine; Zidovudine; Lamivudine vs similar drugs
- Pricing: lopinavir/ritonavir; nevirapine; Zidovudine; Lamivudine cost, discount & access